Bafna Pharmaceuticals Limited - Company Profile

Q: Who are the current directors of Bafna Pharmaceuticals Limited?

The current directors of Bafna Pharmaceuticals Limited are Shanmugam Hemalatha, Mahaveer Chand Bafna, Upendar Mekala Reddy, Melagiri Sridhar, Sundaresan Krishnan Palamadai, Navin Kumar, Akila Chandrashekar Raju, Ravichandran Chitra, Vinayak Dinesh Dendukuri, Bafna Mahaveer Chand, Ashok Barathi Mohanachandran.

It is a pharma public limited company based in Madras 600 001, Tamil Nadu, India, established in 1995.

1995 Madras 600 001, Tamil Nadu, India Active

Last Updated: December 20, 2025

Access Report

About Bafna Pharmaceuticals Limited

Bafna Pharmaceuticals Limited, a active public limited company, was established on 28 March 1995 in Madras 600 001, Tamil Nadu, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: L24294TN1995PLC030698. Registered under ROC Roc Chennai. it is listed on BSE: 532989 and NSE: BAFNAPH. It has an authorized capital of ₹40.00 Cr and a paid-up capital of ₹23.66 Cr.

It upholds a compliant status. In 2024, it reported revenue of ₹155.99 Cr and a net worth of ₹80.84 Cr. Employing 381 professional, Its leadership includes Shanmugam Hemalatha (Whole-Time Director), Upendar Mekala Reddy (Director), Sundaresan Krishnan Palamadai (Director). Past directors included Venkataraman Rajamani, Shanmugam Hemalatha, Nirav Vikram Maniar. It holds ₹68.85 Cr open charges and ₹169.66 Cr settled loans. Its latest AGM occurred on 25 September 2024, with the balance sheet filed on 31 March 2024. It is based at 299, Thambu Chetty Streetmadras 600 001 Madras 600 001, Madras 600 001, Tamil Nadu, 600001.

Company Details

CIN/LLPIN
L24294TN1995PLC030698
Registration Number
030698
Incorporation Date
28 March 1995
Authorized Capital
₹40.00 Cr
Paid-Up Capital
₹23.66 Cr
ROC Code
Roc Chennai
Listing Status
Listed (BSE: 532989, NSE: BAFNAPH)
Company Status
Active

Key Metrics

Authorised Capital ₹ 40.00 Cr as on 20-12-2025
Paid Up Capital ₹ 23.66 Cr as on 20-12-2025
Company Age 30 Year, 10 Months
Last Filing with ROC 31 Mar 2024
Open Charges ₹ 68.85 Cr as on 20-12-2025
Satisfied Charges ₹ 169.66 Cr as on 20-12-2025
Revenue Growth **** 31.50% (FY 2024)
Profit Growth **** -35.19% (FY 2024)
Ebitda **** -29.30% (FY 2024)
Net Worth 10.05% (FY 2024)
Total Assets **** 13.97% (FY 2024)

Comprehensive Company Insights

Explore comprehensive insights into Bafna Pharmaceuticals Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.

Access Report

Who are the key members and board of directors at Bafna Pharmaceuticals Limited?

Current Directors

Name	Designation	Appointment Date	Status
Shanmugam Hemalatha	Whole-Time Director	10 Sep 2020	Current
Upendar Mekala Reddy	Director	26 Jun 2023	Current
Sundaresan Krishnan Palamadai	Director	19 Sep 2025	Current
Navin Kumar	Director	23 Jun 2025	Current
Akila Chandrashekar Raju	Director	10 Sep 2020	Current
Mahaveer Chand Bafna	Ceo	10 Sep 2020	Current

Past Directors

Name	Designation	Cessation	Status
Pramod Abcsdd	Director	25 Jun 2020	Past
Pramod Abcsdd	Whole-Time Director	13 Aug 2021	Past
Pramod Abcsdd	Additional Director	28 May 2018	Past
Pramod Abcsdd	Company Secretary	11 Aug 2022	Past
Pramod Abcsdd	Director	10 Sep 2020	Past
Pramod Abcsdd	Director	20 May 2013	Past

Discover detailed profiles of directors and KMP - Unlock leadership insights today!

Financial Performance of Bafna Pharmaceuticals.

Bafna Pharmaceuticals Limited, for the financial year ended 2024, experienced significant growth in revenue, with a 31.5% increase. The company also saw a substantial fall in profitability, with a 35.19% decrease in profit. The company's net worth Soared by an impressive increase of 10.05%.

Date	Amount	Transaction Name	Valuation	Lead Investors	Investors
Jul, 2021	Amount	Post-IPO - Grab	Valuation	investors	Emtek
Feb, 2021	Amount	Post-IPO - Grab	Valuation	investors	Signite Partners
Jan, 2021	Amount	Post-IPO - Grab	Valuation	investors	Hana Financial Group , GGV Capital
Feb, 2021	Amount	Post-IPO - Grab	Valuation	investors	Signite Partners

Upgrade Required

Full access to Financial is available only for users with an active Premium plan.

Key Matrics
Balance Sheet
Profit and Loss
Cash Flow
Ratios

Metrics

(FY 2023)

YOY Growth

(FY 2022)

(FY 2021)

(FY 2020)

(FY 2019)

Total Revenue

********

31.50%

*******

Revenue from Operations

*******

32.18%

*******

Total Assets

*******

13.97%

*******

Profit or Loss

*******

-35.19%

*******

Net Worth

*******

10.05%

*******

EBITDA

*******

-29.30%

*******

Discover detailed financial data and - Unlock financial today!

What is the Ownership and Shareholding Structure of Bafna Pharmaceuticals?

In 2024, Bafna Pharmaceuticals had a promoter holding of 88.29% and a public holding of 11.70%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Shareholding Pattern (FY 2024)

Promoters: 92.83%
Public: 4.10%
Others: 3.07%

Shareholding Pattern over the Year

	FY (2024)	FY (2023)	FY (2022)	FY (2021)	FY (2020)
Promoters	92.83	94.62	94.55	94.55	94.55
Public	4.10	3.89	3.95	3.96	3.98
Others	3.07	1.49	1.50	1.49	1.47

Upgrade Required

Full access to Ownership and Shareholding Structure is available only for users with an active Premium plan.

Reveal ownership structures and financial performance - Get instant access now!

Charges (Loans)

Open Charges

₹688,510,000.00

Satisfied Charges

₹1,696,600,000.00

Charges Breakdown by Lending Institutions

Others : 68.85 Cr

Latest Charge Details

Date	Lender	Amount	Status
13 Jun 2025	Others	₹11.50 Cr	Open
11 Sep 2024	Others	₹6.35 Cr	Open
21 Feb 2024	Others	₹12.00 Cr	Open
30 Nov 2023	Others	₹12.00 Cr	Open
05 Jun 2023	Others	₹2.00 Cr	Open

Explore comprehensive loan charge details -

How Many Employees Work at Bafna Pharmaceuticals?

Bafna Pharmaceuticals has a workforce of 381 employees as of Mar 31, 2025. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Employee Date	Number of Employees
2020	78,000
2021	80,500
2022	83,200
2023	86,000
2024	89,500
2025	92,000

Upgrade Required

Full access to People is available only for users with an active Premium plan.

Deals i

Gain comprehensive insights into the Deals and Valuation data of Bafna Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bafna Pharmaceuticals's trajectory.

Rating

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Explore deal ratings and alerts - Get instant access now!

Latest Updates, News, and FAQs on Bafna Pharmaceuticals

Recent Activity within the Organization

Director Appointment

The activity Sundaresan Krishnan Palamadai was appointed as a Director was appointed as a Director on 19 Sep 2025 & has been associated with this company since 4 months 23 days . was completed.
19 Sep 2025
Charges

A charge registered on 23 May 2025 via Charge ID 101124057 with Others was fully satisfied on 04 Sep 2025. was recorded as a recent event.
04 Sep 2025
Director Appointment

Navin Kumar was appointed as a Director was appointed as a Director on 23 Jun 2025 & has been associated with this company since 7 months 19 days . was recorded as a recent event.
23 Jun 2025
Charges

A charge with Others amounted to Rs. 11.50 Cr with Charge ID 101111395 was registered on 13 Jun 2025. was recorded as a recent event.
13 Jun 2025
Charges

Progress on A charge with Others of Rs. 20.00 Cr registered on 27 Oct 2021 with Charge ID 100502255 was modified on 13 Jun 2025. was documented.
13 Jun 2025
Charges

The activity A charge with Others amounted to Rs. 10.00 Cr with Charge ID 101124057 was registered on 23 May 2025. was completed.
23 May 2025

Explore recent activity and updates - View Recent Activity